Alebund Pharmaceuticals Jiangsu (SEHK:9637) Jumps After IPO But Is The Valuation Already Priced In

Simply Wall St.07-04

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648693279?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-07-04 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648693279","market":"us","top_or_hot":-1,"title":"Alebund Pharmaceuticals Jiangsu (SEHK:9637) Jumps After IPO But Is The Valuation Already Priced In","media":"Simply Wall St.","content":"<div>\n<p>Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9637/alebund-pharmaceuticals-jiangsu-shares/news/alebund-pharmaceuticals-jiangsu-sehk9637-jumps-after-ipo-but\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alebund Pharmaceuticals Jiangsu (SEHK:9637) Jumps After IPO But Is The Valuation Already Priced In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlebund Pharmaceuticals Jiangsu (SEHK:9637) Jumps After IPO But Is The Valuation Already Priced In\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-04 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9637/alebund-pharmaceuticals-jiangsu-shares/news/alebund-pharmaceuticals-jiangsu-sehk9637-jumps-after-ipo-but><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9637/alebund-pharmaceuticals-jiangsu-shares/news/alebund-pharmaceuticals-jiangsu-sehk9637-jumps-after-ipo-but\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9637/alebund-pharmaceuticals-jiangsu-shares/news/alebund-pharmaceuticals-jiangsu-sehk9637-jumps-after-ipo-but","article_id":"2648693279","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9637/alebund-pharmaceuticals-jiangsu-shares/news/alebund-pharmaceuticals-jiangsu-sehk9637-jumps-after-ipo-but","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648693279","pubTimestamp":1783121101,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares.\nSee our latest analysis for Alebund Pharmaceuticals (Jiangsu).\nThe strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B","IPOS":"Renaissance International IPO ETF","FRHC":"Euronext CAC Health Care","BK4127":"投资银行业与经纪业","KCE":"SPDR KBW Capital Markets ETF"},"translate_title":"江苏艾利邦制药（SEHK：9637）IPO后股价上涨，但估值是否已被定价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCE":1.5,"IPOS":1.5,"FRHC":1.5,"09637":0.9},"content_text":"Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is building off a weaker recent base. If this IPO has you looking at healthcare opportunities tied to medical breakthroughs, it could be a good moment to scan a curated list of 131 healthcare AI stocks. With Alebund Pharmaceuticals (Jiangsu) now trading well above its IPO price and still reporting modest revenue and a substantial loss, the key question is whether the current valuation leaves upside, or if the market is already pricing in future growth. AdvertisementPreferred Price-to-Book of 17.7x: Is It Justified? Alebund Pharmaceuticals (Jiangsu) now trades on a P/B of 17.7x, using the last close of HK$30.28, which stands far above sector and peer levels. The price to book ratio compares the company’s market value to its net assets on the balance sheet. For Alebund Pharmaceuticals (Jiangsu), this P/B of 17.7x sits against revenue of CN¥31m and a reported loss of CN¥750.0m, so the market is valuing its kidney disease pipeline and potential more highly than its current financial footing. Compared with the Hong Kong pharmaceuticals industry average P/B of 1x and a peer average of 1.7x, Alebund Pharmaceuticals (Jiangsu) currently trades at a much richer multiple. That kind of gap usually indicates investors are paying well above both the sector and peer benchmarks for the company’s prospects, while there is no fair ratio estimate available that might suggest a level the P/B could move toward. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 17.7x (OVERVALUED). However, Alebund Pharmaceuticals (Jiangsu) still carries execution risk around getting its kidney therapies through trials, and the reported CN¥750.0m loss keeps funding needs in focus. Find out about the key risks to this Alebund Pharmaceuticals (Jiangsu) narrative. Next Steps Curious whether the mixed signals around Alebund Pharmaceuticals (Jiangsu) point to opportunity or too much risk? Take a close look at both sides of the story and decide quickly where you stand with the 1 key reward and 3 important warning signs. Looking for more investment ideas beyond Alebund Pharmaceuticals (Jiangsu)? If Alebund Pharmaceuticals (Jiangsu) has sharpened your appetite for opportunities, do not stop here. Broaden your watchlist with ideas that match your risk and return preferences.  Target potential mispricing by scanning a curated set of screener containing 498 high quality undiscovered gems that combine strong fundamentals with limited market attention. Strengthen your portfolio core by focusing on companies in the solid balance sheet and fundamentals stocks screener (418 results) that prioritize financial resilience. Reduce portfolio stress by concentrating on the 297 resilient stocks with low risk scores that score well on stability and downside protection.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648693279","isCrawlerRequest":true}